PL3256469T3 - Pochodne (r)-2-metylopiperazyny jako modulatory receptora cxcr3 - Google Patents

Pochodne (r)-2-metylopiperazyny jako modulatory receptora cxcr3

Info

Publication number
PL3256469T3
PL3256469T3 PL16700487T PL16700487T PL3256469T3 PL 3256469 T3 PL3256469 T3 PL 3256469T3 PL 16700487 T PL16700487 T PL 16700487T PL 16700487 T PL16700487 T PL 16700487T PL 3256469 T3 PL3256469 T3 PL 3256469T3
Authority
PL
Poland
Prior art keywords
methyl
receptor modulators
piperazine derivatives
cxcr3 receptor
cxcr3
Prior art date
Application number
PL16700487T
Other languages
English (en)
Inventor
Eva Caroff
Emmanuel Meyer
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL3256469T3 publication Critical patent/PL3256469T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
PL16700487T 2015-01-15 2016-01-14 Pochodne (r)-2-metylopiperazyny jako modulatory receptora cxcr3 PL3256469T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2015050691 2015-01-15
PCT/EP2016/050659 WO2016113346A1 (en) 2015-01-15 2016-01-14 (r)-2-methyl-piperazine derivatives as cxcr3 receptor modulators
EP16700487.8A EP3256469B1 (en) 2015-01-15 2016-01-14 (r)-2-methyl-piperazine derivatives as cxcr3 receptor modulators

Publications (1)

Publication Number Publication Date
PL3256469T3 true PL3256469T3 (pl) 2019-05-31

Family

ID=55129889

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16700487T PL3256469T3 (pl) 2015-01-15 2016-01-14 Pochodne (r)-2-metylopiperazyny jako modulatory receptora cxcr3

Country Status (16)

Country Link
US (1) US10047080B2 (pl)
EP (1) EP3256469B1 (pl)
JP (1) JP6595003B2 (pl)
KR (1) KR102568469B1 (pl)
CN (1) CN107207491B (pl)
AR (1) AR103399A1 (pl)
AU (1) AU2016207990B2 (pl)
BR (1) BR112017015116A2 (pl)
CA (1) CA2972954C (pl)
ES (1) ES2712727T3 (pl)
MX (1) MX2017009292A (pl)
PL (1) PL3256469T3 (pl)
RU (1) RU2706232C2 (pl)
TR (1) TR201901977T4 (pl)
TW (1) TWI698434B (pl)
WO (1) WO2016113346A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658649B (zh) 2013-07-22 2019-03-22 爱杜西亚药品有限公司 1-(哌嗪-1-基)-2-([1,2,4]三唑-1-基)-乙酮衍生物
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
PE20171100A1 (es) * 2015-01-15 2017-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
WO2018011265A1 (en) * 2016-07-13 2018-01-18 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CN110183388A (zh) * 2019-06-06 2019-08-30 常州合全药业有限公司 一种2-（1h-1,2,4-三氮唑-1-乙基）醋酸的合成方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433025A1 (en) 2001-01-23 2002-08-01 Chaoyu Xie Substituted piperidines/piperazines as melanocortin receptor agonists
WO2002059108A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Melanocortin receptor agonists
CA2437594A1 (en) 2001-03-02 2002-09-12 Graham S. Poindexter Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
KR101255356B1 (ko) 2002-06-12 2013-04-17 케모센트릭스, 인크. 염증 및 면역 질병의 치료를 위한 ｃｃｒ１ 길항물질로서사용하기 위한 1-아릴-4-치환된 피페라진 유도체
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
PH12012501891A1 (en) 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US20060276465A1 (en) 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
BRPI0516947A (pt) 2004-10-22 2008-09-23 Janssen Pharmaceutica Nv inibidores de quinase c-fms
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
WO2006088836A2 (en) 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
CA2598459A1 (en) 2005-02-16 2006-08-24 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
MX2007009949A (es) 2005-02-16 2007-09-26 Schering Corp Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3.
EP1856097B1 (en) 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
RU2007134260A (ru) 2005-02-16 2009-03-27 Шеринг Корпорейшн (US) Пиразинилзамещенные пиперазин-пиперидины с антагонистической активностью в отношении cxcr3
MX2007009945A (es) 2005-02-16 2007-09-26 Schering Corp Piperazinas sustituidas con heterociclicos con actividad antagonista de cxcr3.
CA2598460C (en) 2005-02-16 2013-05-07 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
SI1906965T1 (sl) 2005-06-22 2015-09-30 Chemocentryx, Inc. Azaindolne spojine in postopki uporabe
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US20080312215A1 (en) 2005-06-28 2008-12-18 Pharmacopeia Drug Discovery, Inc. Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
JP2009511582A (ja) 2005-10-11 2009-03-19 シェーリング コーポレイション Ｃｘｃｒ３拮抗薬活性を有する置換複素環式化合物
AU2006304897B2 (en) 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
US20090143413A1 (en) * 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
EP1962605A2 (en) * 2005-12-12 2008-09-03 Merck & Co., Inc. 2-arylthiazole derivatives as cxcr3 receptor modulators
WO2007076318A2 (en) 2005-12-21 2007-07-05 Smithkline Beecham Corporation Camphor-derived cxcr3 antagonists
EP1988900A2 (en) 2006-02-23 2008-11-12 Merck & Co., Inc. Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
RU2008141368A (ru) 2006-03-21 2010-04-27 Шеринг Корпорейшн (US) Новые гетероциклические соединения замещенного пиридина с антагонистической активностью схсr3
BRPI0710542B8 (pt) 2006-04-20 2021-05-25 Janssen Pharmaceutica Nv métodos para reduzir e inibir atividade cinase de c-kit em uma célula
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
CA2658417A1 (en) 2006-07-14 2008-01-17 Schering Corporation Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
CN101583610A (zh) 2006-12-22 2009-11-18 先灵公司 具cxcr3拮抗活性的杂环化合物
WO2008091594A2 (en) 2007-01-24 2008-07-31 E. I. Du Pont De Nemours And Company Fungicidal mixtures
JP5337711B2 (ja) 2007-01-25 2013-11-06 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性アミド
MX2010001400A (es) 2007-08-03 2010-04-22 Schering Corp Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas.
TWI428091B (zh) 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
WO2009079490A1 (en) 2007-12-18 2009-06-25 Schering Corporation Process and intermediates for the synthesis of heterocyclic substituted piperazines with cxcr3 antagonist activity
CN101970432B (zh) 2008-01-25 2014-05-28 杜邦公司 杀真菌杂环化合物
JP5535941B2 (ja) 2008-01-25 2014-07-02 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性アミド
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
JP5592350B2 (ja) 2008-04-30 2014-09-17 バイエル・クロップサイエンス・アーゲー 作物保護剤としてのチアゾール−４−カルボン酸エステル及びチオエステル
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
WO2010037479A1 (de) 2008-10-01 2010-04-08 Bayer Cropscience Ag Heterocyclyl substituierte thiazole als pflanzenschutzmittel
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
BRPI0914405B8 (pt) 2008-12-02 2022-12-06 Du Pont Compostos de piperidina carboxamida fungicidas e métodos para o controle de doenças de planta
CN102292334A (zh) 2008-12-11 2011-12-21 拜尔农作物科学股份公司 噻唑基肟醚和腙植物保护剂
US8362249B2 (en) 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
JP5807971B2 (ja) 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
EP2272846A1 (de) 2009-06-23 2011-01-12 Bayer CropScience AG Thiazolylpiperidin Derivate als Fungizide
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
BR112012002369A2 (pt) 2009-08-12 2019-09-24 Syngenta Participations Ag heterociclos microbicidas
WO2011051243A1 (en) 2009-10-29 2011-05-05 Bayer Cropscience Ag Active compound combinations
BR112012010242B1 (pt) 2009-10-30 2018-03-20 Bayer Intellectual Property Gmbh Derivados de heteroarilpiperidina e heteroarilpiperazina
MX2012007200A (es) 2009-12-21 2012-07-10 Bayer Cropscience Ag Bis(difluorometil)pirazoles como fungicidas.
US8952004B2 (en) 2010-01-07 2015-02-10 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
WO2011134969A1 (de) 2010-04-28 2011-11-03 Bayer Cropscience Ag Ketoheteroarylpiperidin und -piperazin derivate als fungizide
US8815775B2 (en) 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
AU2011256730B2 (en) 2010-05-20 2015-07-09 E. I. Du Pont De Nemours And Company Fungicidal oximes and hydrazones
JP2013528169A (ja) 2010-05-27 2013-07-08 バイエル・クロップサイエンス・アーゲー 殺菌剤としてのピリジニルカルボン酸誘導体
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
CA2815716C (en) 2010-10-27 2019-06-11 Bayer Intellectual Property Gmbh Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
EP2643312B1 (en) 2010-11-25 2014-09-10 Syngenta Participations AG Microbicidal heterocycles
MX2013006936A (es) 2010-12-17 2013-07-22 Du Pont Ambas azociclicas fungicidas.
KR101848116B1 (ko) 2011-02-01 2018-04-11 바이엘 인텔렉쳐 프로퍼티 게엠베하 살진균제로서의 헤테로아릴 피페리딘 및 헤테로아릴 피페라진 유도체
BR112013020270A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag derivados de pirazol microbicidas
EP2673272A1 (en) 2011-02-10 2013-12-18 Syngenta Participations AG Microbiocidal pyrazole derivatives
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
JP5959646B2 (ja) 2011-09-15 2016-08-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺菌剤としてのピペリジンピラゾール類
BR112014009086A2 (pt) 2011-10-18 2017-05-09 Syngenta Participations Ag derivados pirazol microbicidas
CN103889982A (zh) 2011-10-18 2014-06-25 先正达参股股份有限公司 杀微生物的吡唑衍生物
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
PT2807153T (pt) 2012-01-25 2020-06-18 Novartis Ag Compostos heterocíclicos e métodos para seu uso
EP2809668B1 (en) * 2012-02-02 2017-04-12 Actelion Pharmaceuticals Ltd. 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives
WO2013127808A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
EP2820012A1 (en) 2012-03-02 2015-01-07 Syngenta Participations AG Microbiocidal pyrazole derivatives
KR101995683B1 (ko) 2012-06-04 2019-07-02 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
WO2014075874A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014075873A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
AP2015008591A0 (en) 2012-12-11 2013-07-31 Takeda Pharmaceutical Heterocyclic compounds
WO2014206896A1 (en) 2013-06-24 2014-12-31 Bayer Cropscience Ag Piperidinecarboxylic acid derivatives as fungicides
CN105658649B (zh) 2013-07-22 2019-03-22 爱杜西亚药品有限公司 1-(哌嗪-1-基)-2-([1,2,4]三唑-1-基)-乙酮衍生物
EP3035800B1 (en) 2013-08-22 2019-10-09 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR102256A1 (es) 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
PE20171100A1 (es) 2015-01-15 2017-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3

Also Published As

Publication number Publication date
JP6595003B2 (ja) 2019-10-23
EP3256469B1 (en) 2018-11-28
TWI698434B (zh) 2020-07-11
RU2706232C2 (ru) 2019-11-15
KR20170102355A (ko) 2017-09-08
AR103399A1 (es) 2017-05-10
CA2972954C (en) 2023-08-29
AU2016207990A1 (en) 2017-08-31
WO2016113346A1 (en) 2016-07-21
RU2017128880A (ru) 2019-02-15
US10047080B2 (en) 2018-08-14
BR112017015116A2 (pt) 2018-04-10
JP2018502162A (ja) 2018-01-25
US20180009800A1 (en) 2018-01-11
RU2017128880A3 (pl) 2019-06-06
AU2016207990B2 (en) 2020-01-30
CN107207491A (zh) 2017-09-26
TW201632518A (zh) 2016-09-16
KR102568469B1 (ko) 2023-08-18
EP3256469A1 (en) 2017-12-20
CN107207491B (zh) 2020-08-25
CA2972954A1 (en) 2016-07-21
ES2712727T3 (es) 2019-05-14
TR201901977T4 (tr) 2019-03-21
MX2017009292A (es) 2018-02-09

Similar Documents

Publication Publication Date Title
ZA201800826B (en) Substituted oxopyridine derivatives
IL252554A0 (en) A history of mutated 2-anilinopyrimidines as egfr modulators
IL274537A (en) nuclear receptor modulators
GB201514875D0 (en) Receptor
GB201518816D0 (en) Receptor
SG11201606876RA (en) Toll like receptor modulator compounds
ZA201802901B (en) Farnesoid x receptor modulators
EP3180332A4 (en) Difluoropyrrolidines as orexin receptor modulators
IL249896A0 (en) Novel modulators of the glp-1 receptor
ZA201605332B (en) Trpa1 modulators
ZA201705486B (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
PL3303293T3 (pl) Modulatory ROR-gamma
PL3303291T3 (pl) Modulatory ROR-gamma
PL3303290T3 (pl) Modulatory ROR-gamma
EP3224261A4 (en) Opioid receptor modulators
IL250247A0 (en) History of piperazine as liver x-receptor modulators
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORγ)
IL254419A0 (en) New pharmaceutical uses
PL3256469T3 (pl) Pochodne (r)-2-metylopiperazyny jako modulatory receptora cxcr3
GB201512714D0 (en) Receptor modulator compounds
GB201407888D0 (en) Novel specific kinase modulators
GB201504285D0 (en) Receptor modulation
GB201521015D0 (en) Novel pharmaceutical uses
GB201505526D0 (en) Novel pharmaceutical uses